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S_nary Breast cancers with an inased lvi ofcathepsin D in tumour tissue extract have been found to
have poor prognosis, but studies performed with immu sy have produced variable results. We
analysed 213 primary invasive breast cancs for aten D ex from ardival tissue with immuno-
histochenistry. The minimum follow-up ofthe patiets still ali was 26 years. Women with ductal can that
lacked D expresso macrophage-like cells had a 75% 5 year and 55% 30 year survival
rate as with only a 401/ 5 year and 20% 30 year survival rate if sromal cels exp d athsn D
(P= 0.0003), whereas cathepsin D expron of cance cefls was asociat with neither val nor the
several prognostc factors investigated Stromal cell catin D was more often present in the ductal than in
the lobular histoogical type (80/I vs 54%, P = 0.002), and its expression was strongly aiat pariarly
with a high cell proliferatin rate. However, m a multivariate analysis stromal cell catin D exp n did
not have independent ifluence on survival in the entire series. We conclude that high suomal cell cathepsin D
expression is associated with a poor short- and long-term outcome in breast cancer.
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Post-operative treatment of women with breast cancer ranges
from observation without further treatment to bone marrow
or peripheral blood stem cell transplantation carried out in
an adjuvant setting. These greatly different therapeutic
decisions are based on individually assessed risk for relapse.
However, none of the prognostic factors available at present
is able to determine the final outcome with certainty, and
there are few data available in the literature on whether the
newer prognostic factors can be used to predict long-term
survival in breast cancer.
The tedency to give rise to distant metastases is an impor-
tant property of cancer cells. One of the molcular mechan-
isms involved in this process may be overproduction of
secretory proteases that degrade the basement membrane and
the extracellular matrix (Rochefort, 1992). The most exten-
sively studied protease in human breast cancer is cathepsin
D, which was first identified as a 52 kDa oestrogen-depen-
dent glycoprotein in MCF-7 cells (Rochefort et al., 1987).
The 52 kDa form is a proenzyme that has active cleavage
products of 48, 34 and 14 kDas. In athymic mice, transfec-
tion of a constitutively expressed cathepsin D gene into a cel
line that does not secrete cathepsin D induces increased
metastatic activity (Garcia et al., 1990). Cathepsin D has
been found to bind to the insulin-like growth factor H (IGF-
II) receptor, and it may thus produce autocrine mitogenic
activity (Mathieu et al., 1990).
Several reports on the prognostic value of cathepsin D in
breast cancer have generally revealed a trend for poor sur-
vival if a high cathepsin D level has been detece (Spyratos
et al., 1989, 1992; Thorpe et al., 1989; Tandon et al., 1990;
Granata et al., 1991; Namer et al., 1991; Duffy et al., 1992;
Kute et al., 1992; Pujol et al., 1993). These analyses have
often been made by enzyme immunoassays or Western blott-
ing from tissue extracts, and none of them includes data on
the effect of cathepsin D on long-term survival. In the pre-
sent study we have investigated the long-term prognostic
value of cathepsin D expression with immunohistochemistry
using a novel monoclonal antibody ICI1. The resuts reveal
that cathepsin D expression of stromal cells, and not cancer
cells, has prognostic value, and that cathepstn D expression




The present series was derived from a larger series (n = 439)
encountered in the city of Turkcu, Finland, in 1945-65. The
series included 95% of all histologically diagosed female
breast carcinomas from this defined area and period, and has
been described in detail elsewhere (Toikanen and Joensuu,
1990). Women with intraductal in situ cancer or Paget's
disease of the breast (n = 15), bilateral cancer (n = 23),
disseminated disease at the time of diagnosis (n = 31) or
those who rived only palliative treatment (n = 22) were
excluded from the analysis. From the remaining 348 cases,
213 cases (61%) with sufficient material available were
analysed for cathepsin D.
The median follow-up period of the patients still alive was
31 years (range 26-43 years). Twenty-seven patients (13%)
were still alive, 130 (61%) had died from breast cancer, nine
(4%) from some cancer other than breast cancer, 46 (22%)
from an intercurrent diseas, and one case the cause of
death remained unkcnown. The median age at diagnosis was
53 years (range 28-89 years). Women <50 years at the time
of the diagosi were considered to be premenopausal, and
those >50 years post-menopausal. Clinical staging was per-
formed retspectvely according to the post-surgical Inter-
national Union Against Cancer tumour-node-metastasis
(TNM) cla tion. One hundred and twenty-eight women
(60%) were treated with radical mastectomy, 45 (21%) had
mastectomy and axillary evacuation, 31 (15%) had mastec-
tomy only and nine (4%) had tumorectomy. Post-operative
radiotherapy was given to 154 (72%) patients.
Histology
New haematoxylin-eosin- and van Gieson-stained slides
were prepared from each tissue block, which were routinely
fixed in neutral formalin and embedded in paraffin. The
histological typing and grading of the tumours were per-
formed with a slight modification of the World Health
Organization (WHO) dassification (1981). Subsequently, the
tumours were grouped into three types: (1) infiltrating ductal
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carcinoma not otherwise specified; (2) infiltrating lobular car-
cinoma; and (3) other special types (tubular, cribriform,
medullary, papillary and pure mucinous carcinomas).
Immwzhistochemical analyses ofcathepsin D and c-erbB-2
Sections from routinely fixed (over 24 h in neutral buffered
formalin) paraffin-embedded blocks were cut on Vectabond-
treated slides (Vector Laboratories, Buringame, CA, USA).
The slides were dewaxed, rehydrated and stained using a
standard avidin-biotin-enhanced inmunoperoxidas techni-
que (Vectastain Elite kit, Vector Laboratories, Burlingame,
CA, USA). The mouse MAb ICIl (IgGI) was used at a
concentration of 50 ngml-' (incubation overnight at +4C).
The production and specificity of the ICI1 antibody have
been described dsewhere (Isola et al., 1993). Western blot
analysis with the ICI1 antibody shows immunorve
bands for the 48 kDa, 34 kDa and 14 kDa cleavage products
of cathepsin D. Diaminobenzidine (0.5 mgml-' in phos-
phate-buffered saline containing 0.03% hydrogen peroxide)
was used as the chromogen. The specificty of immunostain-
ing was controlled with a preadsorption experiment in which
lCII was preincubated with a 100-fold excess of purified
cathepsin D (Sigma, St Louis, MO, USA). All immunostain-
ing of tumour cells and macrophages was abolished by this
preadsorption.
All slides were evaluated for cathepsin D expression in a
binded fashion without any knowledge of the clinical out-
come or other clinicopathological data. The slides were
scored for the percentage of cathepsin D-immunopositive
cancer cells and stromal cells, and for intensity of immuno-
staining. Staining for cathepsin D was visually clasified as
either negative (-) or slightly (+), moderately (++) or
strongly positive (+ + +). To test the repeatability of
classifition, another pathologist classified the same slides
without knowledge of the former classification or other data.
Both cancer cell and stromal cell cathepsin D expression
assessments between the two pathologists correlated well
(P<0.0001 for both), and when survival analyses and other
statistical calculations were repeated usng the classification
reported by the second pathologist, no major changes in the
results were seen.
c-erbB-2 overexpression was d d with a mouse MAb
(TA-250, Triton Digostics, Alameda, CA, USA) using an
immunoperoxidase procedure as described in detail elsewhere
(To;kanen et al., 1992). The stain intensity was scored
visually by using the classi&ation -t +/+ +, whe only the
result + + was consided as positive in the final evalua-
tion.
DNAflow cytometry
DNA flow cytometry was carried out as described in detail
previously (Joensuu et al., 1990) from dewaxed, rehydrated
and pepsin-treated 50pm sections of paraffin-embedded tis-
sue. DNA was stained with propidium iodide. The size ofthe
S-phase fraction was calculated using the rectangular method
(Camplejohn et al., 1989). The median coefficient ofvariation
of the diploid peaks was 7.1% (range 3.1-9.8%). We have
found previously, in an analysis carried out in a blnded
manner, a significant association betwen both DNA non-
diploidy and a high S-phase fraction and survival in the
present series (Joensuu et al., 1990). DNA ploidy was not
determined in 22 cases and S-phase fraction in 92 cases
owing to lack oftissue, overlapping stemlin, the presence of
excessive background debris or the uncertainty of histogram
clasification.
Statistical analyses
Statistical analyses were done with the BMDP computer
program (BMDP Statistical Software, Department of Bio-
mathematics, University of Califoria, Los Angeles, CA,
USA). Frequency tables were analysed with the chi-square
test. The chi-squared test for trend was used for ordinal
variables. Cumulative survival was estimated with the
product-limit method, and comparison ofcumulative survival
between groups was performed with the log-rank test. Sur-
vival corrected for intercurrent deaths was used in statiscal
alculations, and women who died from causes other than
breast cancer were withdrawn from the analysis at the date
of death. Women who died with breast cancer with distant
metastases based on clinical or autopsy evidence were con-
sidered to have died from breast cancer. The relative survival
rate, obtained by dividing the crude survival rate by the
expected rate in the general Finnish female population,
matched for age and the year of follow-up, resulted in a
nearly identical survival curve as was obtained by correcting
for known intecurret deaths, which excludes any major
misclassification in the number of breast cancer deaths (data
not shown). The relative importance of prognostic factors
was analysed using Cox's proportional hazard model (BMDP
2L). All P-values are two-sided.
Redts
Expression ofcathepsin D in breast cancer
Forty-nine (23%) cancers showed no immunoreactivity for
cathepsin D in malignant epithelial cells, and 66 (31%) had
slight, 66 moderate and 32 (15%) strong staining for cathep-
sin D. No staining for cathepsin D was found in stromal cells
in 52 (24%) cases, slight staining in 73 (34%), moderate
staining in 60 (28%) and strong snig in 28 (13%).
Excamples of staining results are shown in Figure 1. Immuno-
staning resulted in cytoplasmic immunoreactivity, which was
granular in 63% of the samples, compatible with the
a
b
Fgwe I Examples of immunhistohlog staining results for
cathepn D with MAb ICI1. a, Strong stainig of stromal
nmarophage-like cells for cathepsin D, but tumour cells are
negaive. b, No stainng in stromal cells, but tumour cells are
strongly positive. Original magification x 100.Somal catepsin D in breas cancer
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lysosomal localisation of the antigen. In the rest of the cases
immunoreactivity was of a more diffuse type, which may
reflect poorer preservation of lysosomes in these samples. The
stromal cells stained with IC I antibody were mostly
macrophage-like tumour-infiltrating cells. No significant
association was found between staining of tumour cells and
stromal cells for cathepsin D (P = 0.25).
Clinicopathologicalfeatures of tumours with high cathepsin D
expression
Expression of stromal cell cathepsin D was strongly assoc-
iated with several clinicopathological features (Table I). A
particularly strong association was found between stromal
cell cathepsin D and cell proliferation rate. Only two (3%) of
the cancers with more than three mitoses per high-power field
had negative stromal cell staining for cathepsin D as com-
pared with 44% among cancers with a low mitotic count
(P<0.0001). Similarly, only 16% of the cancers with an
S-phase fraction larger than the median had stromal cells
negative for cathepsin D as compared with 33% of the
cancers with an S-phase fraction smaller than the median
(P = 0.02). Cancers of the lobular histological type more
often had stromal cells negative for cathepsin D than ductal
cancers (46% vs 20%, P = 0.002). No significant correlation
was found between stromal cell cathepsin D expression and
age at diagnosis, degree of tumour fibrosis or c-erbB-2
oncoprotein expression (determined in only 132 cases).
Tumour cell cathepsin D was not significantly associated
with any of these factors or those listed in Table I.
Table I Correlation of cathepsin D expression with nine
clinicopathological features in 213 patientsa with breast cancer
Stromal cell cathepsin D
Negative Positive
n (0) n (%o
Feature - + ++ +++ P
Mitotic count high-power field
Rare 31 (44) 39 (56)
2-3 19 (23) 63 (77)
>3 2 (3) 59 (97) <0.0001
Histological grade
1 18 (43) 24 (57)
II 25 (27) 67 (73)
III 9 (11) 70 (89) 0.0001
Tumour necrosis
None 41 (34) 79 (66)
Spotty moderate severe 11 (12) 82 (88) 0.0002
Axillary nodal status
pNO 25 (41) 36 (59)
pN+ 18 (16) 94 (84) 0.0003
Inflammatory cell reaction in and around tumour
None or slight 7 (13) 49 (87)
Moderate 7 (18) 33 (82)
Severe 38 (32) 79 (68) 0.003
Histological type
Ductal 33 (20) 128 (80)
Lobular 16 (46) 19 (54)
Special 3 (18) 14 (82) 0.006
DNA ploidy
Diploid 21 (35) 39 (65)
Non-diploid 24 (18) 107 (82) 0.01
S-phase fraction
$g8% (median) 21 (33) 42 (66)
>8% 9 (16) 49 (84) 0.02
Primary tumour size
pTl 11 (41) 16 (59)
pT2 30 (24) 95 (76)
pT3-4 11 (18) 50 (82) 0.03
'Post-surgical axillary nodal status was not available in 40cases. DNA
ploidy in 22 and S-phase fraction in 92 cases.
Survival
Cathepsin D staining of cancer cells had no association with
survival corrected for intercurrent deaths. All staining inten-
sity levels (no vs slight vs moderate vs strong staining) were
tested as a cut-off level, but none resulted in a significant
difference in survival. Similarly. cancer cell cathepsin D was
not associated with prognosis among node-negative, node-
positive, premenopausal or post-menopausal women.
The presence of cathepsin D immunostaiing in stromal
cells was strongly associated with an unfavourable outcome.
Cases with slight to strong staining had similar outcome and
were, therefore, combined in survival analyses (Figure 2).
Cancers that lacked cathepsin D expression in stromal
macrophages (n = 52, 24%) were associated with a 77% 5
year. 58% 10 year and 50% 30 year survival rate as com-
pared with a 50% 5 year, 38% 10 year and 29% 30 year
survival rate among cases with at least some cathepsin D
expression (P = 0.0007).
Positive stromal cell cathepsin D staining (light to strong
staining vs no staining) was associated with unfavourable
outcome among both premenopausal (n = 92, P= 0.003) and
post-menopausal women (n = 121. P = 0.06), and in node-
positive (pN +) breast cancer (n = 112. P = 0.04). No signifi-
cant association between stromal cell cathepsin D staining
and survival was found among the node-negative cases (pNO.
n = 61, P = 0.55). If only women with ductal histological
type of cancer were included in the analysis (n = 161), women
with cancer with stromal cells negative for cathepsin D had
as high as 75% 5 year and 55% 30 year survival rate as
compared with only 40% 5 year and 20% 30 year survival
rate among those with positive staining for cathepsin D
(P = 0.0003; Figure 2).








Fgwe 2 Influence of stromal cell cathepsin D (CD) expression
on survival among 213 women with breast cancer a, and in the
subgroup of ductal breast cancer b. n = 161). The patients still
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D expression was a weaker prognostic factor than stromal
cell cathepsin D expression alone. The combined effect of
tumour and stromal cells was investigated by assigning a
score from 0 to 3 for both cancer cells and stromal cells, and
testing the sum of the scores for survival; or testing the
highest one of the two scores in a survival analysis. Cancers
with a diffu staining pattern had somewhat poorer outcome
than those with the granular pattern (P = 0.05).
Multivariate analyses
To assess the independent prognostic value of stromal cell
cathepsin D determination, it was compared with other prog-
nostic factors in a multivariate analysis. Several dasscal
prognostic factors were associated with unfavourable survival
in a univariate analysis in the present series, and they
included the presence of axillary nodal metastases at diag-
nosis (pN+ vs pNO, P<0.0001), a large primary tumour size
(pT3-4 vs pT2 vs pTl, P<O.0001), poor histological grade
of differentiation (grade IIH vs grade H vs grade I,
P<0.0001), a high mitotic count (>3 mitoses per high-
power field vs 2-3 vs rare, P<0.0001), and the ductal his-
tological type (ductal vs lobular vs the specialised types,
P<0.0001). When stromal cell cathepsin D expression was
tested together with these factors using Cox's stepwise
analysis, only axillary nodal status (relative risk 4.2, 95%
confidence interval 2.4-7.1), the primary tumour size (2.2,
1.6-3.1), histological grade (1.6, 1.2-2.2) and histological
type (1.6, 1.02-2.5) had independent prognostic value.
Similarly, stromal cell cathepsin D expression did not have
independent prognostic value when tested among patents
with node-negative disease, node-positive disease, those with
ductal breast cancer or post-menopausal women, but it had
prognostic value among premenopausal women (2.8, 1.1-7.1)
together with axillary nodal status (4.6, 1.8-11.8), primary
tumour size (2.2, 1.3-3.9) and histological type of cancer
(3.3, 1.4-7.9).
Expression of stromal cell cathepsin D was associated with
poor prognosis and several established adverse prognostic
factors in breast cancer, such as a high mitotic count, poor
histological grade of differentiation and positive axillary
nodal status, whereas tumour cell cathepsin D expression was
associated with none of these factors. Until recently, tumour
cell stroma has been considered to play a passive role in the
growing cancer, but now a considerable body ofevidence has
accumulated suggesting a more active participation of
stromal cells in the process of invasion.
Several proteases are active in stromal cells of malignant
tumours. In human adenocarcinoma of the colon, urokinase-
type plasminogen activator (uPA), which specifically activates
the conversion of plasminogen to the broad substrate spec-
trum protease plasmin, can be found by immunohistochemis-
try in the fibroblast-like cells in tumour stroma, but not in
the malignant epithelial cells (Grondahl-Hansen et al., 1991).
Similarly, its mRNA is expressed by fibroblast-like stromal
cells adjacent to the invasive tumour nodules (Pyke et al.,
1991). Interstitial collagenase immunoreactivity is also
located in stromal cells (Hewitt et al., 1991), as well as
mRNAs for 72 kDa type IV collagenase (Poulson et al.,
1992) and 92 kDa collagenase (Dano et al., 1993). Similarly,
in ductal mammary carcinoma urokinase-type plasminogen
activator mRNA is expressed by stromal fibroblast-like cells
and occasionally by cancer cells, mRNA for 92 kDa type IV
collagnase is expressed by tumour-infiltrating macrophages
(Dano et al., 1993) and mRNA of the putative metallopro-
tease stromelysin-3 is expressed by fibroblast-like cells (Basset
et al., 1990). Expression of these proteases may be up-
regulated by paracrine stimulatory growth factors excreted
by tumour cells, or protease inhibitors may be suppressed by
such factors.
Cathepsin D is a protease, and it may be involved in the
process of tumour cell invasion, degradation of extracellular
matrix, breakdown of the basement membrane and metas-
tasis formation. It may behave as a processing protease able
to be autoactivated and to process and activate other pro-
teases (Rochefort, 1992). Furthermore, cathepsin D may act
as a growth factor. In vitro studies have suggested that
cathepsin D can stimulate the proliferation of MCF-7 cells in
an autocrne manner (Vignon et al., 1986), and it may pro-
mote cell growth by binding to IGF-II receptor (Mathieu et
al., 1990). In line with these findings, we found strong
cathepsin D expression of stromal cells to be associated with
a high mitotic count and a high S-phase fraction size. A high
stromal cell cathepsin D level has been found to be assoc-
iated with a high S-phase fraction in another study (Isola et
al., 1993), but cytosol cathepsin D level has correlated neither
with the S-phase fraction size (Kute et al., 1992) nor with the
tritiated thymidine labelling index (Paradiso et al., 1992).
In univariate analyses, several studies performed on breast
cancer tissue extracts using enzyme immunoassays or
Western blotting have found an increased cathepsin D level
to be associated with unfavourable overall survival (Spyratos
et al., 1989; Duffy et al., 1992; Pujol et al., 1993), recurrence-
free survival (Spyratos et al., 1989, 1992; Thorpe et al., 1989;
Pujol et al., 1993) or with poor outcome in a subgroup such
as women with oestrogen receptor-positive cancer (Granata
et al., 1991), node-negative cancer (Tandon et at., 1990; Kute
et al., 1992) or node-positive breast cancer (Namer et al.,
1991). Moreover, in multivariate analyses a high tumour
extract cathepsin D level has had independent prognostic
value regarding overall or recurrence-free survival in series
consisting of both node-negative and node-positive breast
cancer (Spyratos et al., 1989; Thorpe et al., 1989; Namer et
al., 1991; Pujol et al., 1993), or in the subgroups of node-
negative (Tandon et al., 1990; Kute et al., 1992) or node-
positive disease (Namer et al., 1991).
Immunohistochemistry performed with antibodies that
work in deparaffinised tissue may provide advantages over
the cytosol assays, because it allows easy access to archival
material with a known outcome and separate analysis of
cathepsin D expression in cancer cells and other cells. Assess-
ment of immunohistochemical staining of frozen breast
cancer sections for cathepsin D has given similar results as
cytosol immunoenzymatic assays performed on the same
tumours (Maudelonde et al., 1992). However, while studies
on cytosol assays of cathepsin D have consistently reported
high levels to be associated with poor outcome, studies based
on immunohistochemistry have resulted in variable conclu-
sions. Some studies fail to detect any survival disadvantage
for cathepsin D-positive breast cancer patients (Domagala et
al., 1992), while some report a survival advantage (Henry et
al., 1990) and others a disadvantage (Isola et al., 1993) for
patients with high cathepsin D immunoreactivity. Reasons
for such a discrepancy may lie in the properties of the
antibody used, differences between the series and treatments
given, or a failure to recognise the prognostic importance of
stromal cell cathepsin D expression.
In line with the present findings, Brisson et al. (1993)
recently found, in a series of node-positive breast cancer
patients with a median follow-up of 6 years, cathepsin D
staining of tumour cells to have no prognostic value, whereas
staining of stromal cells was associated with decreased
disease-free survival, Furthermore, they found positive stain-
ing of stromal cells to be associated with higher histological
and nuclear grades.
The association between high stromal cell cathepsin D
expression and poor survival found in the present study may
reflect the degree of tumour macrophage infiltration. Further
studies now need to be performed in order to characterise the
macrophage-like tumour-infiltrating cells that express cathep-
sin D, and to determine whether the degree of tumour
macrophage infiltration has any correlation with survival in
breast cancer.
In conclusion, the present data indicate that tumour
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histochemistry is a prognostic variable in breast cancer.
Stromal cell cathepsin D expression is strongly associated
with poor long-term survival in this disease. and deserves to
be further evaluated in other series of breast cancer.
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